Jim Cramer of CNBC 'Mad Money' sat down with Rob Friel, chairman and CEO of PerkinElmer. Shares of PerkinElmer (NYSE: PKI) are up 20% in 2018.
Recent Media Coverage
Read recent articles about PerkinElmer below. Clicking a headline will take you to the publication’s website for the full article.
On this edition of Bloomberg Baystate Business, Rob Friel, CEO of PerkinElmer, talks about the company’s recently released second quarter earnings report.
The FDA has cleared PerkinElmer’s lupus diagnostics for sale in the U.S. PerkinElmer designed the tests to run on its automated EUROPattern microscope, thereby cutting turnaround times.
Although cisplatin is clinically proven to combat numerous human cancers – bladder, head and neck, lung, ovarian, testicular – resistance to treatment remains a key challenge, and cisplatin patients can often relapse.
Foundation Medicine and Illumina have amended their supply and service agreement and extended the terms of the agreement through June 6, 2023, according to a document filed with the US Securities and Exchange Commission by Foundation Medicine on Thursday.
This study uses single-cell inductively coupled plasma–mass spectrometry (ICP-MS) and discusses the steps required for a successful single-cell ICP-MS analysis using a mammalian case study of the uptake of cisplatin into ovarian cancer cells and an ecotoxicological example of the uptake of dissolved and nanoparticulate gold into freshwater algae cells.
Mass spectrometry is a go-to method for determining which molecules are in a sample. If security officers are faced with an unknown, possibly dangerous, substance, they don’t want to waste time sending samples to a lab and waiting for mass spec results, however. They’d rather be able to take a portable mass spec into the field to get answers quickly.
Elsevier has announced a strategic collaboration with PerkinElmer to integrate the companies chemistry software platforms.
Texas A&M AgriLife Research and their internationally recognized Genomics and Bioinformatics Service are poised to change the face of agriculture-focused genomics.
With the 2016 publication of ICH E6R2, organizations in the pharmaceutical space have been taking a fresh look at their Insource/Outsource strategies, in particular around analytics for clinical development.
Almost every industry is being exposed to the prevalence of opportunities provided by the internet of things (IoT). In fact, the number of connected “things” will reach 20.4 billion by 2020.
According to a story from wired.com, a new genomics marketplace called Helix will soon start selling genetic tests directly to consumers.
By 2022, the global next-generation sequencing (NGS) market has been projected to reach between $10.5 billion (BCC Research) and $12.45 billion (MarketsandMarkets), though a more cautious forecast envisions that market growing a bit more slowly, to $11.92 billion by 2024 (BIS Research).
PerkinElmer said today that Parent Project Muscular Dystrophy (PPMD) has selected it to provide genetic testing for its Decode Duchenne program, a no-cost testing and counseling effort for people with Duchenne who otherwise could not afford genetic analyses.
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
First trimester screening for pre-eclampsia (PE) can be improved using a combination of maternal factors and biomarkers, according to a study published online March 14 in Ultrasound in Obstetrics & Gynecology.
C&EN's ranking of scientific equipment makers reflects strong sales to a broad range of customers.
With the alcoholic beverage market booming in the U.S., the safety and quality of both domestic and imported products must be assured.
A collaboration between researchers from Flinders University and the University of Adelaide has used a new game-changing robot to mass-screen almost 3000 drugs to find potential treatments to help protect millions of unborn babies around the world from the presently incurable Zika Virus.
The 90-day-long, worldwide competition will ask its thousands of participants to train deep learning models for the express purpose of analyzing cell images and identifying nuclei across different experiments, without biologist intervention.
GEN's Panel Gives Expert Advice on Which Format Is Best